|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2001-7-16
|
|
pubmed:abstractText |
Infliximab is an anti-tumor necrosis factor alpha monoclonal antibody IgG effective in the treatment and maintenance of remission of active refractory Crohn disease and associated draining enterocutaneous fistulae. Multiple infusions of infliximab show promising results in patients with rheumatoid arthritis. Currently, there is limited clinical experience with infliximab, and no published reports exist on its use in cutaneous disorders.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0003-987X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
137
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
930-3
|
|
pubmed:dateRevised |
2008-3-17
|
|
pubmed:meshHeading |
pubmed-meshheading:11453813-Adult,
pubmed-meshheading:11453813-Antibodies, Monoclonal,
pubmed-meshheading:11453813-Crohn Disease,
pubmed-meshheading:11453813-Dermatologic Agents,
pubmed-meshheading:11453813-Female,
pubmed-meshheading:11453813-Humans,
pubmed-meshheading:11453813-Infusions, Parenteral,
pubmed-meshheading:11453813-Male,
pubmed-meshheading:11453813-Middle Aged,
pubmed-meshheading:11453813-Psoriasis,
pubmed-meshheading:11453813-Pyoderma Gangrenosum,
pubmed-meshheading:11453813-Rectal Fistula,
pubmed-meshheading:11453813-Skin,
pubmed-meshheading:11453813-Treatment Outcome,
pubmed-meshheading:11453813-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody.
|
|
pubmed:affiliation |
Department of Dermatology, Box 1047, The Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA.
|
|
pubmed:publicationType |
Journal Article,
Case Reports
|
